Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chelsee J Jensen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The American Journal of Managed Care|March 22, 2023
Neulasta Onpro: a coup de grâce?Chelsee J Jensen, Caleb J Scheckel, Ronald S Go, et al.
JAMA Network Open|January 25, 2022
Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020Aakash Desai, Caleb Scheckel, Chelsee J Jensen, et al.
Mayo Clinic Proceedings|March 26, 2022
Implementing and Optimizing Biosimilar Use at Mayo ClinicChelsee J Jensen, Eric M Tichy, Mary B Lempke, et al.
Journal of the American Pharmacists Association : Japha|October 29, 2025
The Three-fer: How Biosimilars Reduce Cost, Expand Access, and Improve MarginTina M Seekamp, Michael Hamacher, Jason A Kemper, et al.
JCO Oncology Practice|May 26, 2022
Economic Cost and Sustainability of Oral Therapies in Precision OncologyAakash P Desai, Caleb J Scheckel, Leah C Soderberg, et al.
American Journal of Hematology|March 28, 2026
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and SalesLucas T Go, Lewis T Go, Michelle A Elliott, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
JCO Oncology Practice|April 15, 2025
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The American Journal of Managed Care|March 22, 2023
Neulasta Onpro: a coup de grâce?Chelsee J Jensen, Caleb J Scheckel, Ronald S Go, et al.
JAMA Network Open|January 25, 2022
Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020Aakash Desai, Caleb Scheckel, Chelsee J Jensen, et al.
Mayo Clinic Proceedings|March 26, 2022
Implementing and Optimizing Biosimilar Use at Mayo ClinicChelsee J Jensen, Eric M Tichy, Mary B Lempke, et al.
Journal of the American Pharmacists Association : Japha|October 29, 2025
The Three-fer: How Biosimilars Reduce Cost, Expand Access, and Improve MarginTina M Seekamp, Michael Hamacher, Jason A Kemper, et al.
JCO Oncology Practice|May 26, 2022
Economic Cost and Sustainability of Oral Therapies in Precision OncologyAakash P Desai, Caleb J Scheckel, Leah C Soderberg, et al.
American Journal of Hematology|March 28, 2026
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and SalesLucas T Go, Lewis T Go, Michelle A Elliott, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
JCO Oncology Practice|April 15, 2025
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Pageof 1